Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High throughput screening identifies repurposable drugs for modulation of innate and acquired immune responses.
Ghorbanalipoor S, Matsumoto K, Gross N, Heimberg L, Krause M, Veldkamp W, Magens M, Zanken J, Neuschutz KJ, De Luca DA, Kridin K, Vidarsson G, Chakievska L, Visser R, Kunzel S, Recke A, Gupta Y, Boch K, Vorobyev A, Kalies K, Manz RA, Bieber K, Ludwig RJ. Ghorbanalipoor S, et al. J Autoimmun. 2024 Sep;148:103302. doi: 10.1016/j.jaut.2024.103302. Epub 2024 Aug 19. J Autoimmun. 2024. PMID: 39163739 Free article.
Corrigendum: Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases.
Ghorbanalipoor S, Emtenani S, Parker M, Kamaguchi M, Osterloh C, Pigors M, Gross N, Khil'chenko S, Kasprick A, Patzelt S, Wortmann D, Ibrahim IO, Izumi K, Goletz S, Boch K, Kalies K, Bieber K, Smith P, Schmidt E, Ludwig RJ. Ghorbanalipoor S, et al. Front Immunol. 2022 Nov 30;13:1099535. doi: 10.3389/fimmu.2022.1099535. eCollection 2022. Front Immunol. 2022. PMID: 36532003 Free PMC article.
Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases.
Ghorbanalipoor S, Emtenani S, Parker M, Kamaguchi M, Osterloh C, Pigors M, Gross N, Khil'chenko S, Kasprick A, Patzelt S, Wortmann D, Ibrahim IO, Izumi K, Goletz S, Boch K, Kalies K, Bieber K, Smith P, Schmidt E, Ludwig RJ. Ghorbanalipoor S, et al. Front Immunol. 2022 Sep 28;13:865241. doi: 10.3389/fimmu.2022.865241. eCollection 2022. Front Immunol. 2022. PMID: 36248903 Free PMC article.
Pathogenic Activation and Therapeutic Blockage of FcαR-Expressing Polymorphonuclear Leukocytes in IgA Pemphigus.
Emtenani S, Ghorbanalipoor S, Mayer-Hain S, Kridin K, Komorowski L, Probst C, Hashimoto T, Pas HH, Męcińska-Jundziłł K, Czajkowski R, Recke A, Sunderkötter C, Schneider SW, Hundt JE, Zillikens D, Schmidt E, Ludwig RJ, Hammers CM. Emtenani S, et al. Among authors: ghorbanalipoor s. J Invest Dermatol. 2021 Dec;141(12):2820-2828. doi: 10.1016/j.jid.2021.06.007. Epub 2021 Jul 8. J Invest Dermatol. 2021. PMID: 34246620 Free article.
Propranolol Is an Effective Topical and Systemic Treatment Option for Experimental Epidermolysis Bullosa Acquisita.
Stüssel P, Schulze Dieckhoff K, Künzel S, Hartmann V, Gupta Y, Kaiser G, Veldkamp W, Vidarsson G, Visser R, Ghorbanalipoor S, Matsumoto K, Krause M, Petersen F, Kalies K, Ludwig RJ, Bieber K. Stüssel P, et al. Among authors: ghorbanalipoor s. J Invest Dermatol. 2020 Dec;140(12):2408-2420. doi: 10.1016/j.jid.2020.04.025. Epub 2020 May 22. J Invest Dermatol. 2020. PMID: 32450072 Free article.
Protective effect of TSLP and IL-33 cytokines in ulcerative colitis.
Tahaghoghi-Hajghorbani S, Ajami A, Ghorbanalipoor S, Hosseini-Khah Z, Taghiloo S, Khaje-Enayati P, Hosseini V. Tahaghoghi-Hajghorbani S, et al. Among authors: ghorbanalipoor s. Auto Immun Highlights. 2019 Mar 14;10(1):1. doi: 10.1186/s13317-019-0110-z. Auto Immun Highlights. 2019. PMID: 30868311 Free PMC article.
ADF Winter School-An exciting concept of the Arbeitsgemeinschaft Dermatologische Forschung to connect young scientists and clinician scientists in Dermatology at the top of Germany.
Yazdi AS, Barlin M, Böhm K, Gendrisch F, Ghorbanalipoor S, Häberle S, Hamel A, Hüning S, Hüttner C, Iwanova I, Kanaki T, Kimeswenger S, Lohmann N, Munir S, Muzumdar S, Pereira MP, Peking P, Plesser K, Rendon A, Rentschler M, Schlumprecht C, Smorodchenko A, Stock M, Tillmanns J, Uslu U, Ghoreschi K, Glatz M, Grabbe S, Kunz M, Ludwig R, Scharffetter-Kochanek K, Loser K. Yazdi AS, et al. Among authors: ghorbanalipoor s. Exp Dermatol. 2017 Mar;26(3):292-294. doi: 10.1111/exd.13241. Epub 2016 Nov 3. Exp Dermatol. 2017. PMID: 27808431 No abstract available.
PDE4 Inhibition as Potential Treatment of Epidermolysis Bullosa Acquisita.
Koga H, Recke A, Vidarsson G, Pas HH, Jonkman MF, Hashimoto T, Kasprick A, Ghorbanalipoor S, Tenor H, Zillikens D, Ludwig RJ. Koga H, et al. Among authors: ghorbanalipoor s. J Invest Dermatol. 2016 Nov;136(11):2211-2220. doi: 10.1016/j.jid.2016.06.619. Epub 2016 Jul 5. J Invest Dermatol. 2016. PMID: 27388992 Free article.